MEMBER LOGIN: Your Email: Password: Remember Me
Forgot Your Password or would like to register?
JNJ Johnson & Johnson
As Of 8/17/2018 7:11:00 PM
Current Price$134.47
Current Rating3
Return Since 9/2015
Johnson & Johnson 53.23 %
S&P 50044.21 %
VFS Rating Analysis
Market ReturnAverage
return vs market
Related Links
Company News
Earnings Call Transcripts
Options Chain
Options Pricing History
For current estimates, historical performance information and more, Log in to your account.

Monthly Performance and Prediction History
Below is the monthly performance history for this security and the monthly change as compared to the stock market for this security. When a row is highlighted in green, it is identifying a stock that the model predict will outperform the portfolio for that month. When a row is highlighted in red, it is identifying a stock that the model predicted will underperform for the month. No highlight indicates the model is neutral on the stock. These predictions are always recorded at the beginning of the month, and table below shows the resulting return for the month.
DateVFS RatingPredictionRating PriceSubsequent
% Increase
Market %
Increase *
8-01-20182 $132.52   
5-01-20183 $126.49-4.72%2.43%-7.15%
4-01-20182 $128.15-1.30%0.52%-1.81%
3-01-20182 $129.88-1.33%-3.13%1.80%
* As measured by the performance of the S&P 500 for the month.

JNJ14See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ14Buy Johnson & Johnson, Now Poised to Rally ( 11:12:00 AM
JNJ14See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ14See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ14Daabon Strikes Deal With Avicanna, Becoming The Largest Agro Company To Enter The Cannabis Industry ( 1:07:00 PM
JNJ13See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ13Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report? ( 6:59:00 AM
JNJ13See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ13NYSE trader: Stocks could drop in August ( 11:41:00 AM
JNJ13Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference ( 11:04:00 AM
JNJ13Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference ( 10:56:00 AM
JNJ9Drug distributor Cardinal's profit beats on pharma unit strength ( 4:29:00 AM
JNJ9How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs ( 4:42:00 PM
JNJ8Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study ( 1:24:00 AM
JNJ8A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity ( 9:00:00 AM
JNJ8Better Buy: AbbVie Inc. vs. Johnson & Johnson ( 3:01:00 AM
JNJ8Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus ( 5:52:00 AM
JNJ8Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations ( 2:30:00 PM
JNJ4Jury orders Monsanto to pay $289 million in Roundup cance... ( 11:39:00 AM
JNJ4The Philosophy of Dividend Aristocrat Stocks ( 11:19:00 AM
JNJ4Shire, Shionogi File NDA for Intuniv for Adults in Japan ( 9:36:00 AM
JNJ43 Biotech Stocks With Major Catalysts Incoming ( 5:17:00 AM
JNJ4The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers ( 4:38:00 AM
JNJ4Trump seeks out business leaders as midterm election looms ( 7:27:00 AM
JNJ4Q2 Earnings Drive Pharma ETFs Higher ( 6:50:00 AM
JNJ43 Reasons Geron Corporation Stock Could Be a Big Winner ( 11:30:00 AM
JNJ4Tesaro: Lower Fiscal 2018 Guidance, Share Price Fell on August 3 ( 5:03:00 AM
JNJ4A Performance Overview of Merck’s Virology and Immunology Drugs ( 4:31:00 AM
JNJ4The 4 Cheapest 'Dividend Kings' to Buy Today ( 9:00:00 AM
JNJ3The Top UPS Shareholders (UPS) ( 11:48:00 AM
JNJ3What Does Baxter International’s Valuation Trend Indicate? ( 8:46:00 AM
JNJ3A Closer Look at Allergan’s Business Segments in Q2 2018 ( 8:05:00 AM
JNJ34 Mega-Cap Stocks to Buy As They’re Thrust Into the Spotlight ( 6:50:00 AM
JNJ3Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication ( 6:34:00 AM
JNJ3A Look at Allergan’s Valuation on August 16 ( 5:03:00 AM
JNJ3HBJ health care panel talks tech innovation, high patient costs ( 11:18:00 AM
JNJ3Trump administration proposes production quota cuts for six opioids ( 10:54:00 AM
JNJ3A Look at the Performance of Bausch Health’s Ortho Dermatologics ( 7:31:00 AM
JNJ3Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation ( 5:44:00 AM
JNJ3Most Analysts Are Optimistic about Vertex Pharmaceuticals ( 5:09:00 AM
JNJ3Should Gilead Be Worried About This New Monthly HIV Medication? ( 4:19:00 AM
JNJ3Rare Genetic Mutation May Help Drugmakers Battle Obesity ( 2:49:00 PM
JNJ3A Performance Overview of Bausch + Lomb ( 9:55:00 AM
JNJ3SurveyMonkey adds Emory dean to board of directors, balancing its gender representation ( 9:28:00 AM
JNJ33 Reasons Cisco Systems Stock Can Surge to $50 ( 8:37:00 AM
JNJ3Factbox: U.S. companies with exposure to Russia ( 2:18:00 PM
JNJ3Generic Drugmakers Struggle Despite U.S. Push for Copycats ( 11:09:00 AM
JNJ3Examining Pfizer’s Valuation as of August 6 ( 6:00:00 AM
JNJ3These Products Saw Falling Sales in Pfizer’s Q2 2018 ( 7:31:00 AM
JNJ3Pfizer’s Quarterly Revenue Trend in Q2 2018 ( 8:30:00 AM

WEBSITE DISCLAIMER:  Puget Investors and Vertical Financial Systems, Inc are not registered investment advisers, broker/dealers, or research analysts/organizations. The content on this website is issued solely for information purposes and should not to be construed as an offer to buy, sell, or trade in any way, any security mentioned herein.

All information presented on this website is believed to be reliable and written in good faith, but no representation or warranty, expressed or implied is made as to their accuracy, completeness or correctness. You are responsible for doing your own research before investing in any securities mentioned herein. Readers are urged to consult with their own independent financial advisors with respect to any investment. Neither Vertical Financial Systems, Inc, nor its officers or employees accept any liability whatsoever for any direct or consequential loss arising from any use of information on this website.

Past performance is not a guarantee of future performance or accuracy. Rating calculations and methodology may change at any time, and we reserve the right to make changes which may impact the accuracy of the model without prior notice to anybody.

Be advised that employees and officers of Vertical Financial Systems, Inc and may hold positions in the securities mentioned in this website.
Website Operated by Vertical Financial Systems, Inc